Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- DSP Mounts Attack on Market for Antihypertensives with 7 Products with Different MOA
June 16, 2008
- 44th Annual Meeting of ASCO
June 16, 2008
- EPS to Embark on Chinese Business in Earnest
June 16, 2008
- R&D NEWS IN BRIEF
June 16, 2008
- Teijin to Defend Top Market Share for Drugs for Osteoporosis: Mr Nishikawa
June 9, 2008
- Marketing Excellence Japan 2008
June 9, 2008
- Erbitux, Thymoglobulin, Mycobutin Recommended for Approval
June 9, 2008
- FJPWA Sets Common Goal for Price Agreement Rate at 70% by End Sept.
June 9, 2008
- Galderma's Adapalene, INO Therapeutics' Inoflow Recommended for Approval
June 9, 2008
- NPhA Members Exchange Opinions with Major Wholesalers
June 9, 2008
- Approval Recommended for OTC Version of Miconazole for Vaginal Candidiasis
June 9, 2008
- BUSINESS NEWS IN BRIEF
June 9, 2008
- Departure of Global Companies from Japan Is Serious Problem: Mr Yagi
June 9, 2008
- Top 4 Generic Makers' Combined Sales Up 9.4% to \138.9 Bil.
June 9, 2008
- DVx's Excimer Laser Lead Withdrawal System Recommended for Approval
June 9, 2008
- Sawai: Sales Up 9.7% with Double-digit Fall in Profits
June 9, 2008
- Guidelines on HRT to Be Completed in November
June 9, 2008
- Towa Pharm.: Sales, Profits Fall Short of Mid-Term Plan
June 9, 2008
- Sutent Drug of Choice for Progressive RCC
June 9, 2008
- GENERICS NEWS IN BRIEF
June 9, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…